Wednesday, October 30, 2013 1:36:39 PM
Aegis Capital raises their STML tgt to $70 from $40. Co has reported favorable preclinical data for its lead drug candidate, SL-401, in areas such as multiple myeloma and chronic myelogenous leukemia (CML). In firm's view, market authorization for SL-401 in MM and additional niche hematological malignancies on top of blastic plasmacytoid dendritic cell neoplasm and acute myeloid leukemia could drive peak sales potential from $800mm to over $3bn. Further, Stemline's follow-up candidate to SL-401, known as SL-501, is a variant interleukin-3-diphtheria toxin fusion protein that could be used to target CML as a new product.
Read more: http://www.briefing.com/InPlayEq/InPlay/InPlayDual.htm#ixzz2jEBkpn66
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM